April 8, 2022

Press Release

**Reborna Biosciences, Inc.**

## Reborna Biosciences, Inc. Named a Finalist in Two Categories for the Informa Pharma Intelligence Awards 2022

Reborna Biosciences, Inc. announced that it has been named a finalist in the Informa Pharma Intelligence Awards 2022 in two categories: Biotech Company of the Year - Private and Licensing Deal of the Year.   The Awards are the Japanese equivalent of the Scrip Awards, which have been held in the UK for 17 years and are known worldwide.

The Awards, held for the first time in Japan, recognize outstanding advancements and innovations in Japanese pharmaceutical and biotech companies, highlighting Japan's integral role in the global healthcare market.

These inaugural Awards bring together leading innovators and reflect on life-changing accomplishments made over the previous year.   Final winners will be announced at an awards ceremony on Thursday, September 1, 2022.

For more information, please visit the following link:

https://pharmaintelligence.informa.com/ja-jp/events/awards/japan-awards-2022/shortlist-jp

**About Reborna Biosciences, Inc.**

Reborna is engaged in drug discovery research for oral drugs that show disease-modifying effects through normalizing RNA function by using small molecule drugs with high affinity for RNA. We will contribute to society by providing new drugs that enable patients suffering from rare genetic diseases and their families to feel that they have been reborn. For more information, please visit http://rebornabiosciences.com.